FDA
-
-
-
-
-
-
-
Denali Therapeutics Inc. (DNLI) PT Raised to $40 at Goldman Sachs
-
-
-
-
-
-
-
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
-
-
-
-
-
-
-
Denali Therapeutics outlines 2026 milestones including Hunter syndrome launch
-
-
-
-
-
-
-
Denali Therapeutics secures $275 million royalty deal with Royalty Pharma
-
-
-
-
-
-
-
FDA extends review timeline for Denali's Hunter syndrome treatment
-
-
-
-
-
-
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
-
-
-
-
-
-
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
-
322,967 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

